Emitab Tablet

Introduction

Emitab Tablet 5 mg is a medication classified as a phenothiazine antipsychotic. It is primarily used to manage severe nausea and vomiting, and to treat psychotic disorders such as schizophrenia. Prochlorperazine also has antianxiety and sedative properties.

Uses

Emitab Tablet 5 mg is used for:

• Managing severe nausea and vomiting, including that associated with chemotherapy and post-operative recovery.
• Treating psychotic disorders such as schizophrenia.
• Alleviating severe anxiety and agitation in certain conditions.
• Providing sedation for various medical procedures.

Mechanism of Action

Prochlorperazine works by blocking dopamine receptors in the brain, particularly the D2 receptor subtype. This action helps reduce symptoms of psychosis and nausea by modulating neurotransmitter activity in the central nervous system. It also has anticholinergic and antihistaminic properties that contribute to its therapeutic effects.

How Long Does It Take to Work?

Patients may start to experience relief from nausea and vomiting within 30 minutes to 1 hour after oral administration. For psychotic symptoms, it may take several weeks of consistent use to observe significant therapeutic effects. The onset of action can vary based on the condition being treated and the individual patient's response.

Absorption

Prochlorperazine is well absorbed from the gastrointestinal tract. The peak plasma concentration occurs approximately 2 to 4 hours after oral administration. The drug's absorption is not significantly affected by food intake.

Route of Elimination

Prochlorperazine is primarily metabolized in the liver. It is excreted mainly in the urine as metabolites, with a smaller amount excreted in the feces. The drug undergoes extensive first-pass metabolism, which can affect its systemic availability.

Dosage

The dosage of Emitab Tablet 5 mg varies based on the condition being treated:

• For nausea and vomiting: The typical dose is 5 to 10 mg, taken orally 3 to 4 times a day as needed. Doses can be adjusted based on patient response and tolerance.
• For psychotic disorders: The usual dose is 10 to 20 mg, taken orally 2 to 3 times a day. The dose may be adjusted based on clinical response and tolerability.
• For sedation: The dose is individualized and depends on the procedure and patient condition. It is typically administered before the procedure.

Administration

Prochlorperazine can be administered orally in the form of tablets, orally disintegrating tablets, or rectal suppositories. It can also be given intramuscularly in certain acute situations. The oral tablets should be taken with or without food, and the dosage should be consistent with the prescribing guidelines.

Side Effects

Common side effects include:

• Drowsiness.
• Dizziness.
• Dry mouth.
• Constipation.
• Weight gain.

Serious side effects may include:

• Extrapyramidal symptoms such as tremors, rigidity, and bradykinesia.
• Tardive dyskinesia with long-term use.
• Neuroleptic malignant syndrome (NMS).
• Severe hypotension.

Toxicity

In cases of overdose, symptoms may include severe sedation, hypotension, extrapyramidal symptoms, and anticholinergic effects. Treatment involves supportive care, monitoring vital signs, and symptomatic management. In severe cases, the use of activated charcoal and/or antidotes such as benztropine may be necessary.

Precautions

Precautions include:

• Use with caution in patients with a history of cardiovascular disease or hypertension.
• Monitor for signs of extrapyramidal symptoms and tardive dyskinesia, especially with long-term use.
• Assess liver function periodically due to the drug's hepatic metabolism.

Interaction

Prochlorperazine may interact with:

• CNS depressants: Increased risk of sedation and respiratory depression.
• Anticholinergic drugs: Potential for enhanced anticholinergic effects.
• Drugs affecting hepatic metabolism: May alter Prochlorperazine levels.

Disease Interaction

Use with caution in patients with:

• Parkinson's disease or other conditions with extrapyramidal symptoms.
• Severe liver impairment, which may affect drug metabolism and clearance.
• Pre-existing cardiovascular conditions, including arrhythmias.

Drug Interaction

Drug interactions include:

• Levodopa: May reduce the effectiveness of Prochlorperazine.
• Antihypertensive medications: Prochlorperazine may enhance hypotensive effects.
• Other antipsychotics: Concomitant use may increase the risk of adverse effects.

Food Interactions

There are no significant food interactions with Prochlorperazine, but it is recommended to take it consistently with or without food to maintain stable plasma levels.

Pregnancy Use

Prochlorperazine is classified as Category C for pregnancy. It should be used during pregnancy only if the potential benefits outweigh the risks. Consult a healthcare provider before use during pregnancy.

Lactation Use

Prochlorperazine is excreted in breast milk in small amounts. The use of Prochlorperazine during lactation should be evaluated for potential benefits and risks. Consult a healthcare provider to determine if it is appropriate during breastfeeding.

Acute Overdose

In case of acute overdose, symptoms may include severe sedation, hypotension, and extrapyramidal symptoms. Immediate medical attention is required, and treatment typically involves supportive care and symptomatic management. Activated charcoal may be used if the overdose is recent.

Contraindication

Contraindications include:

• Hypersensitivity to Prochlorperazine or any component of the formulation.
• Comatose states or severe CNS depression.
• Patients with bone marrow suppression or blood dyscrasias.

Use Direction

Follow the prescribed dosage and administration instructions. Prochlorperazine should be taken as directed, with doses not exceeding the recommended amounts. Consistent dosing schedules should be maintained, and missed doses should be taken as soon as remembered unless it is almost time for the next dose.

Storage Conditions

Store Prochlorperazine at room temperature, away from moisture and heat. Keep it out of reach of children and dispose of any unused medication properly.

Volume of Distribution

The volume of distribution for Prochlorperazine is approximately 5 to 10 L/kg, indicating its distribution in body tissues and fluids.

Half Life

The elimination half-life of Prochlorperazine is approximately 6 to 8 hours, which supports its dosing regimen for effective symptom management.

Clearance

Prochlorperazine is primarily cleared through hepatic metabolism. Its clearance rate can be influenced by liver function and the use of other medications that affect hepatic metabolism.

See in details version Emitab Tablet 5 mg also Emitab Tablet 5 mg in bangla

Some Frequently Asked Questions About Emitab Tablet 5 mg